<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20130304012695N14</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-09-04</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Ropivacaine-Dexmedetomidine infiltration with Ropivacaine at the wound edge in reducing pain after open kidney surgeries.</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of subcutaneous infiltration of Dexmedetomidine plus Ropivacaine and Ropivacaine alone in the surgical wound site in reducing pain after kidney surgery with flank incision.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-10-02</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/65569</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: For the randomization of patients who meet the inclusion criteria, the method of four blocks including intervention and control groups will be used.The preparation of randomization sequences will be done using the Random Generator software and the created sequences will be given to a trained staff member of the operating room who is not a member of the research group.The researchers of this study will not be aware of the existing sequences and arrangement of the blocks.After the patient enters the operating room, the trained person removes the first sequence from the special box of this study and according to the predetermined protocol, if it is D, it will be transferred to the intervention group, and if it is C, it will be transferred to the control group, Blinding description: In this study, patients do not know their group.Eligible participants were assigned to receive either Ropivacaine (group R) or Diphenhydramine as (group D) according to a computer-generated randomization schedule. These medications are prepared in identical syringes and volumes and are identified with the patient name and hospital registration number. At the end of the surgery, these drugs are given to the surgeon for injection, who is blinded to the    allocation groups. Another researcher who is blinded to the assigned group will assess the severity of pain in the recovery room and ward.</study_design>
      <phase>2-3</phase>
      <hc_freetext>local anesthetic effect of Dexmedetomidine.</hc_freetext>
      <i_freetext>Intervention 1: Control group: 20 ml of ROPIVACAINA 0.5%,   (made by Molteni company Italia) is prepared with the help of a neurse   of anesthesiology according to the patient's grouping, and the surgeon injects it under the skin before completely closing the wound on both sides of the wound edge.After wound closure and endotracheal tube extubation, the patient was transferred to the recovery room, and data about the study variables is collected in the recovery and ward section.If patients have severe pain, morphine (made by Caspian Tamin company) will be used for postoperative analgesia. Intervention 2: Intervention group: 20 ml of ROPIVACAINA 0.5%,   (made by Molteni company Italia)along plus100 micrograms of dexmedetomidin (manufactured by Darou Darman Arang factory) is prepared with the help of a neurse   of anesthesiology according to the patient's grouping, and the surgeon injects it under the skin before completely closing the wound on both sides of the wound edge.After wound closure and endotracheal tube extubation, the patient was transferred to the recovery room, and data about the study variables is collected in the recovery and ward section.If patients have severe pain, morphine (made by Caspian Tamin company) will be used for postoperative analgesia.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Main study outcome data

When:
Six months after the end of the study

To whom:
University researchers

Conditions:
Share experiences to increase the knowledge

Where to obtain:
khajavim@tums.ac.ir -Dr.khajavi

How to obtain:
The request will be made by email and the answer will be given within two months

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammadreza Khajavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sina Hospital,Immam Khominie St</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 6312 1220</telephone>
        <email>khajavim@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammadreza Khajavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sinai Hospital,Imam Khomeini Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 6312 1220</telephone>
        <email>khajavim@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients who have the consent to participate in the study
Patients who are candidates for open kidney surgery</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of allergies to the drugs used
History of addiction to drugs or other psychotropic substances
History of psychological disorder</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: 20 ml of ROPIVACAINA 0.5%,   (made by Molteni company Italia) is prepared with the help of a neurse   of anesthesiology according to the patient's grouping, and the surgeon injects it under the skin before completely closing the wound on both sides of the wound edge.After wound closure and endotracheal tube extubation, the patient was transferred to the recovery room, and data about the study variables is collected in the recovery and ward section.If patients have severe pain, morphine (made by Caspian Tamin company) will be used for postoperative analgesia.</i_keyword>
      <i_keyword>Intervention group: 20 ml of ROPIVACAINA 0.5%,   (made by Molteni company Italia)along plus100 micrograms of dexmedetomidin (manufactured by Darou Darman Arang factory) is prepared with the help of a neurse   of anesthesiology according to the patient's grouping, and the surgeon injects it under the skin before completely closing the wound on both sides of the wound edge.After wound closure and endotracheal tube extubation, the patient was transferred to the recovery room, and data about the study variables is collected in the recovery and ward section.If patients have severe pain, morphine (made by Caspian Tamin company) will be used for postoperative analgesia.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Total analgesics consumption during the first 24 hr after surgery. Timepoint: One time at the end of the first 24 hours after operation. Method of measurement: According to the patient file and nursing report.</prim_outcome>
      <prim_outcome>When was the first need for analgesics. Timepoint: During 6 hours after surgery. Method of measurement: In terms of time per minute, and according to the first time after extubation of patients, the analgesic is injected.</prim_outcome>
      <prim_outcome>Acute Postoperative Pain. Timepoint: In recovery room and 1,6,12,18 and 24 hours after surgery. Method of measurement: Visual Analog Scale(VAS score).</prim_outcome>
      <prim_outcome>Agitation and Sedation degree. Timepoint: In recovery room and 1,6,12,18 and 24 hours after surgery. Method of measurement: Ramsy Sedation Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-06-22</approval_date>
        <contact_name>Research Ethics Committees of Sina Hospital ,Tehran University of Medical Sciences</contact_name>
        <contact_address>Sinai Hospital,Imam Khomeini street Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
